Insight Molecular Diagnostics Inc. Common Stock IMDX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Kitted Products | $0— | $0— | $0-100% | $24K— | $0— | |
| Laboratory Services | $32K-97.2% | $1.14M+338% | $260K-47.4% | $494K-76.9% | $2.14M+43.9% | |
| Accounts Receivable Net Current by Product | ||||||
| Kitted Products | $0— | $0— | $0-100% | $24K— | —— | |
| Laboratory Services | $159K-85.5% | $1.1M+321% | $261K-47.1% | $493K— | —— | |
| Concentration Risk % by Product | ||||||
| Kitted Products | 0%— | —— | 0%-5.0pp | 5%— | 0%— | |
| Laboratory Services | 100%— | —— | 100%+5.0pp | 95%-5.0pp | 100%+95.0pp | |
| Non-Current Assets by Geography | ||||||
| Asia Pacific | $36K-42.9% | $63K-29.2% | $89K-23.3% | $116K-18.9% | $143K-15.9% | |
| Europe | $1.72M+8.8% | $1.58M+22.2% | $1.29M-4.8% | $1.36M-2.7% | $1.39M+128% | |
| GB | $407K-6.0% | $433K-5.7% | $459K-5.4% | $485K-5.1% | $511K— | |
| US | $6.75M-5.9% | $7.18M+54.4% | $4.65M-1.4% | $4.72M-7.7% | $5.11M-7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insight Molecular Diagnostics Inc. Common Stock break its business down?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) reports revenue by product across 2 parts — Kitted Products and Laboratory Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Insight Molecular Diagnostics Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insight Molecular Diagnostics Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
